CION Ameerpet
Kidney cancer · Hereditary & genetics
Von Hippel-Lindau (VHL) disease and kidney cancer — what carrying the gene actually means
Von Hippel-Lindau disease is inherited, and it is not a cancer in itself. It is a fault in one gene, carried from birth, that removes a safeguard against certain growths — in the kidney, and in a handful of other organs. What it changes is not whether you can be looked after, but how: VHL kidney tumours are found earlier, watched on a schedule, and treated in a way that protects kidney function for the long run. This page explains that plainly, for someone who has just been told the words.
- VHL is a predisposition, not a diagnosis of cancer — many of the growths it causes are benign, and kidney involvement develops over time rather than being present from birth.
- VHL kidney tumours behave differently — younger, often in both kidneys and in more than one place, and usually slow-growing, which is why they are watched before they are treated.
- Counselling, testing, imaging and surveillance are in-house — led by medical oncology at CION. Kidney-sparing surgery and ablation are coordinated with specialist urology and interventional radiology at partner centres.
- 45-minute consultation, free — bring the family history and any scans or reports you already have, and leave with a plan rather than a search history.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The plain explanation
What VHL disease is, and why it involves the kidney
One gene, carried from birth. Von Hippel-Lindau disease is caused by a fault in the VHL gene. Everyone has two copies of it, and its job is to help the cell clear away a signal that tells tissue to build new blood vessels. In VHL disease one faulty copy is inherited, and is therefore present in every cell of the body from the moment you exist. That single faulty copy is not enough on its own to cause a growth — but it means any cell that later loses its remaining working copy has lost the brake entirely. That is why growths appear in more than one organ, and in more than one place within an organ.
Why the growths are so full of blood vessels. When the VHL brake is gone, the blood-vessel signal builds up unchecked and the cell behaves as though it were starved of oxygen. It recruits vessels. This is why the tumours of VHL — in the retina, in the brain and spinal cord, and in the kidney — are characteristically vascular, and it is also why the kidney cancer VHL causes is almost always the clear cell type. The same biology explains why targeted treatment classes that act on blood-vessel signalling have a role in advanced clear cell kidney cancer generally.
How it passes through a family. VHL is autosomal dominant. Only one faulty copy is needed, so each child of a parent who carries it has an even chance of inheriting it, and it affects men and women equally. Not everyone with VHL has an affected parent: the fault can also arise new in one person, which is why a family with no history at all can still be the family in which VHL is first identified. If you are trying to work out whether an inherited cause is even likely in your family, start with is kidney cancer hereditary? — most kidney cancer is not — and then read when to suspect hereditary kidney cancer.
What it does to the kidney specifically. Two things, and they are not the same thing. The commoner is cysts: fluid-filled spaces that often appear in both kidneys and, on their own, are not cancer and do not need removing. The other is clear cell renal cell carcinoma, which can develop alongside those cysts, typically at a younger age than kidney cancer usually appears, often in both kidneys, and often as several separate tumours rather than one. Finding a cyst on a VHL scan is expected, and is not the same as finding a cancer — that distinction is one your radiologist and your oncologist make together, not one to draw yourself from a report.
And what it does elsewhere. VHL is not a kidney condition that happens to be inherited; it is a whole-body condition that includes the kidney. Growths in the retina, in the brain and spinal cord, in the adrenal gland, in the pancreas and in the inner ear are all part of the same picture, which is why surveillance is organised across organs rather than for the kidney alone. We have set that out separately in VHL beyond the kidney. For the disease itself — types, staging, symptoms and treatment in general — the kidney cancer guide is the place to start.
If you have not been told you have VHL and are here because of a symptom or a scan finding, this is not the page that answers your question. Book a free consultation and have the finding itself looked at properly first.
Did you know?
In VHL disease the goal is not to remove every tumour as soon as it is seen. Because the tumours are usually slow-growing and more will appear over a lifetime, treating each one on sight would cost more working kidney than the disease itself. So small tumours are measured and watched on a planned schedule, and treated only once they cross a size the team has agreed in advance — preserving kidney function is a goal in its own right, not an afterthought.
What changes, and what does not
How VHL kidney cancer behaves differently
These are the features that make a specialist manage VHL kidney tumours on their own terms rather than as ordinary kidney cancer. None of them is a reason for alarm on its own — together they are why the plan looks the way it does.
Age
It appears younger
Kidney cancer without an inherited cause becomes commoner with each decade from middle age. In VHL it tends to appear well before that. A young age at diagnosis is one of the first things that makes a specialist consider an inherited syndrome at all, and it is one of the situations for which NCCN guidance recommends genetic risk evaluation.
Both sides
Both kidneys, and more than one tumour
Sporadic kidney cancer is usually one tumour on one side. VHL commonly produces tumours in both kidneys, and several separate tumours in the same kidney, because every kidney cell started with the same disadvantage. What that means for treatment planning is set out in bilateral and multifocal kidney tumours.
Tumour type
Clear cell, almost always
Each inherited kidney syndrome has its own characteristic tumour type, and the VHL one is clear cell renal cell carcinoma. That is one of the things separating it from hereditary papillary RCC, from Birt-Hogg-Dubé syndrome and from HLRCC, which behave differently and are managed differently.
Cysts too
Cysts alongside tumours
VHL kidneys frequently carry cysts, often on both sides. A cyst is a fluid-filled space, not a tumour, and most need nothing done. What the radiologist watches for is a cyst with solid components, or one that takes up contrast, because those features change how closely it is followed. Expect cysts to be mentioned on your reports; they are part of the picture, not bad news in themselves.
Pace
It usually grows slowly
This is the most reassuring feature of VHL kidney disease, and the one that makes planned surveillance safe rather than negligent. Slow growth is what allows a small tumour to be measured, re-measured and left alone until it reaches an agreed size, instead of being treated the moment it appears at the cost of working kidney tissue.
Whole body
The kidney is not watched alone
Surveillance in VHL covers the eye, the nervous system, the adrenal gland, the pancreas and the inner ear as well as the kidney, on schedules that do not all run at the same interval. That coordination is a large part of what specialist care for VHL actually is — see VHL beyond the kidney.
VHL is not the only inherited condition that involves the kidney, and the differences matter. Kidney growths in tuberous sclerosis, for example, are most often angiomyolipomas rather than cancers, and are managed on entirely different lines. Which syndrome is in play changes what is watched, how often, and what treatment is right — which is why confirming it properly is worth doing.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
VHL is managed, not just diagnosed
A 45-minute consultation to go through the family history, the scans you already have, and the surveillance schedule that should be running.
What happens, in order
How VHL kidney care is organised, step by step
Most of this is not treatment. VHL care is mainly a schedule — kept properly, reviewed each time, and adjusted when something changes. Treatment is the part that happens occasionally, not the part that defines it.
Genetic counselling comes before any test
Not after it. Counselling is where the family history is drawn out properly on both sides, where it is decided whether testing would actually change anything, and where what a result would mean — for you and for your relatives — is explained before anyone consents to it. At CION this is led in-house by medical oncology. What genetic counselling for kidney cancer involves walks through the appointment itself.
Confirming the diagnosis
VHL is recognised either from the pattern — a kidney tumour at a young age, tumours in both kidneys, or a kidney growth alongside a growth in the eye, nervous system, adrenal gland or pancreas — or because it is already known in the family. A blood sample is then used to look for a fault in the VHL gene. NCCN guidance recommends genetic risk evaluation for exactly these situations: young age at diagnosis, bilateral or multifocal tumours, or affected close relatives.
Testing the rest of the family
This is where a confirmed VHL result does the most good. Once the family fault is known, relatives can be tested for that specific fault, and the answer is clean either way: those who did not inherit it need no surveillance and can stop worrying, and those who did can begin planned monitoring long before anything could cause trouble. Genetic testing and your family covers how that conversation is handled, including with children.
Setting up lifelong surveillance
Surveillance in VHL is not one scan repeated forever. It is a schedule across organs, at intervals set by the team according to what has been found and how it has behaved. For the kidney that usually means MRI or ultrasound, with CT where it adds something, arranged and reported in-house at CION and reviewed at each visit rather than filed. The schedule is written down and given to you, because it has to survive changes of address, of doctor and of decade.
Watching a small kidney tumour, and knowing when to act
A small VHL kidney tumour is measured and followed rather than treated on sight, because more will appear over a lifetime and working kidney has to last. When one reaches the size the team agreed in advance, it is dealt with by a kidney-sparing method — treating the tumour rather than removing the kidney, or destroying it with heat or cold. Those procedures are performed by specialist urology and interventional radiology at partner centres and coordinated by CION; they are not carried out in-house.
If disease becomes advanced, treatment is systemic
Where kidney cancer in VHL has spread beyond what local treatment can handle, care moves to systemic therapy led in-house by medical oncology — immunotherapy, combination immunotherapy, and targeted classes that act on the blood-vessel and oxygen-sensing pathways this disease disturbs. We name classes and mechanisms here rather than individual medicines, because the right one depends entirely on the person. Kidney cancer treatment in Hyderabad sets out the options properly.
One thing this page deliberately will not do is put a lifetime percentage on your risk of kidney cancer with VHL, or a figure in centimetres on when a tumour should be treated. Published figures describe groups, thresholds are set by a team looking at your kidneys, and quoting either here would give false precision. Both are answerable in a consultation, with your scans in front of the person answering.
A condition you live with, looked after properly
Get the schedule written down and the family sorted out
Counselling, testing, imaging and long-term surveillance in one place, with the same team reading the scans each time.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
VHL disease and kidney cancer - your questions answered
What is von Hippel-Lindau (VHL) disease?
VHL disease is an inherited condition caused by a fault in a single gene, the VHL gene, which normally acts as a brake on the growth of new blood vessels. Because the fault is carried from birth it is present in every cell of the body, and that is why VHL can produce growths in several organs rather than one — the kidney, the adrenal gland, the pancreas, the brain and spinal cord, the retina and the inner ear. VHL is not a cancer in itself. It is a predisposition: it removes one safeguard, so certain tumours become more likely, tend to appear earlier in life, and often appear in more than one place. Many of the growths it causes are benign.
Does everyone with VHL disease get kidney cancer?
No. Kidney involvement is common in VHL but it is not universal, and it is not there from birth — it develops over time, which is exactly why surveillance exists. Many people with VHL first develop kidney cysts rather than tumours, and a cyst is not a cancer. When a kidney cancer does develop it is almost always the clear cell type, it is usually found while it is still small, and it can usually be treated with the kidney preserved. We deliberately do not quote a lifetime percentage here, because published figures describe groups and say very little that is reliable about one person. What your own risk looks like depends on your family variant and your scan history, and that is a conversation for your specialist.
How is VHL kidney cancer different from ordinary kidney cancer?
Three things set it apart. It appears younger, often well before the age at which kidney cancer usually shows up. It is frequently in both kidneys, and in more than one place in the same kidney, rather than a single tumour on one side. And it tends to grow slowly. Together those change the whole approach: the aim is not only to deal with the tumour but to protect enough working kidney to last a lifetime, because someone with VHL may need treatment more than once over many years. That is why small VHL kidney tumours are usually watched on a schedule and treated with kidney-sparing methods once they reach a size the team has agreed in advance.
How is VHL disease diagnosed?
Usually in one of two ways. Either a specialist recognises the pattern — a kidney tumour at a young age, tumours in both kidneys, or a kidney growth alongside a growth in the eye, nervous system, adrenal gland or pancreas — or the condition is already known in the family and relatives are offered testing. Either way the step before testing is genetic counselling, which at CION is led in-house by medical oncology. A blood sample is then used to look for a fault in the VHL gene. A confirmed result matters well beyond the person tested: it lets at-risk relatives be tested and, where they carry it, be offered planned surveillance instead of waiting for symptoms.
How often do the kidneys need scanning if I have VHL disease?
There is no single interval that fits everyone. Surveillance in VHL is lifelong and it is planned by the team rather than fixed by a rule: how often you are scanned depends on what has already been found, how quickly anything present has changed, your age, and what is being watched in the other organs at the same time. Kidney imaging is usually MRI or ultrasound, with CT where it adds something, and it is arranged and reported in-house at CION. The important part is that the schedule is written down and kept to. Surveillance is what turns VHL from something that catches people out into something found early and dealt with calmly.
Can VHL kidney cancer be treated successfully?
In most cases the kidney tumours of VHL are found small, grow slowly, and are treated with the kidney preserved, and people live with the condition for decades under surveillance. Treatment is staged rather than one-off: small tumours are watched, and when one reaches the agreed threshold it is removed or ablated in a kidney-sparing way. Those procedures are carried out at specialist partner centres, coordinated by CION with specialist urology and interventional radiology, rather than in-house. Where disease has spread, care moves to systemic treatment — targeted and immunotherapy classes, led in-house by medical oncology. No one can promise an individual outcome, and this page does not; what it can say is that VHL kidney cancer found early is very often controllable.
This page is general information about an inherited condition, not a diagnosis, a genetic result or a personal risk assessment. Only a specialist who has taken your family history, seen your scans and, where appropriate, arranged genetic testing can tell you what VHL means for you and what your own surveillance schedule should be.